Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an open‐label, non‐randomized, multicenter phase 1b trial of venetoclax with azacitidine (AZA; 75 mg/m 2; days 1‐7) or decitabine (DEC; 20 mg/m 2; days 1‐5). Endpoints included safety, response rates (complete remission [CR], CR with incomplete blood count recovery [CRi]), response duration and overall survival (OS). The median follow‐up time was 29 and 40 months for patients treated with venetoclax plus AZA and DEC combinations, respectively. Key Grade ≥ 3 AEs (AZA and DEC) were febrile neutropenia (39% and 65%), anemia (30% and 26%), thrombocytopenia (25% and 23%), and neutropenia (20% and 10%). The CR/CRi rate was 71% for venetoclax plus AZA and 74% for venetoclax plus DEC. The median duration of CR/CRi was 21.9 months and 15.0 months, and the median OS was 16.4 months and 16.2 months, for venetoclax plus AZA and DEC, respectively. These results support venetoclax plus hypomethylating agents as highly effective frontline AML therapies for patients unfit for intensive chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900 · cited 2×
“Response rates differ in patients with intermediate vs poor-risk cytogenetics in the context of LDAC, azacitidine, or decitabine monotherapy show moderate difference in response rates between patients with intermediate-risk and poor-risk cytogenetics (between 3%-13%).(25,34) In this study, rates of CR/CRi were similar…”
BackgroundSelf-citationDiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825 · cited 5×
“The clinical experience of escalating doses of venetoclax combined with either azacitidine or decitabine in newly diagnosed older patients with AML who were ineligible for standard induction chemotherapy demonstrated high rates of durable responses.(13,14) These venetoclax plus hypomethylating agent (HMA) combination…”
BackgroundMethodInfluentialSelf-citationDombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165 · cited 3×
“Importantly, the benefits of venetoclax-based therapy come in the context of a manageable safety profile.(1,5) As is expected from patients with AML, most key adverse events were hematologic in nature, and patients treated with venetoclax plus either HMA had rates of grade three (or higher) cytopenia that were similar…”
BackgroundResultHoward, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044 · cited 1×
“Laboratory and clinical TLS were identified as previously defined.(21) Per protocol, for patients with ongoing cytopenia(s) after morphologic clearance of leukemia, subsequent cycles of venetoclax and HMA could be delayed until ANC reached ≥500/μL or for up to 14 days to allow for blood count recovery.”
MethodFenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778 · cited 1×
“Recent data propose that the leukemia stem cell (LSC) population is targeted by venetoclax with azacitidine, due to its specific disruption of amino acid-fueled oxidative phosphorylation, on which the LSC population is uniquely reliant.(11,12) The clinical experience of escalating doses of venetoclax combined with eit…”
BackgroundSelf-citationWei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692 · cited 7×
“As is expected from patients with AML, most key adverse events were hematologic in nature, and patients treated with venetoclax plus either HMA had rates of grade three (or higher) cytopenia that were similar to previously-reported venetoclax-based low intensity therapies in older patients with AML.(33) In addition, a…”
ResultInfluentialSelf-citationBurnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619 · cited 1×
“The reported response rate of azacitidine and decitabine monotherapy in newly diagnosed AML patients who are at least 65 years old ranges between 10 and 50% CR/CRi,(1,5,26-28) with median OS between 6 and 12 months.(29,30) Here, the addition of venetoclax to the backbone therapy provided over 16 months of OS regardles…”
BackgroundInhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Jones, C. L., Stevens, B. M., D'Alessandro, A., Reisz, J. A., Culp-Hill, R., Nemkov, T., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.005 · Cited by 585
Self-citation
Metadata
- Authors
- Pollyea, D. A., Pratz, K., Letai, A., Jonas, B. A., Wei, A. H., Pullarkat, V., Konopleva, M., Thirman, M. J., Arellano, M., Becker, P. S., Chyla, B., Hong, W., Jiang, Q., Potluri, J., & DiNardo, C. D.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2020-11-10
- Volume
- 96
- Issue
- 2
- Pages
- 208-217
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3095201154
- Cited by
- 166
- References
- 10
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study. https://app.cochat.ai/papers/10.1002/ajh.26039
- The paper
- Pollyea, D. A., Pratz, K., Letai, A., Jonas, B. A., Wei, A. H., Pullarkat, V., Konopleva, M., Thirman, M. J., Arellano, M., Becker, P. S., Chyla, B., Hong, W., Jiang, Q., Potluri, J., & DiNardo, C. D. (2021). Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study. American Journal of Hematology. https://doi.org/10.1002/ajh.26039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.